Meeting
2018 ASCO Annual Meeting
Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
Authors
Richard D. Kim
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Richard D. Kim , Andrew Stewart Poklepovic , Andrew B. Nixon , Dae Won Kim , Heloisa P. Soares , Jun Min Zhou , Fatima Tariq , Natalie Burgess , Hanna Kelly Sanoff , Jongphil Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02115542
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4082)
DOI
10.1200/JCO.2018.36.15_suppl.4082
Abstract #
4082
Poster Bd #
271
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).
First Author: Dae Won Kim
Poster
2016 Gastrointestinal Cancers Symposium
Multi-institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
First Author: Heloisa P. Soares
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
First Author: Raed Moh'd Taiseer Al-Rajabi
Poster
2023 ASCO Annual Meeting
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
First Author: William Joseph Chapin